129 related articles for article (PubMed ID: 18053198)
1. A prospective, randomised, controlled clinical study on the assessment of tolerability and of clinical efficacy of Merional (hMG-IBSA) administered subcutaneously versus Merional administered intramuscularly in women undergoing multifollicular ovarian stimulation in an ART programme (IVF).
Alviggi C; Revelli A; Anserini P; Ranieri A; Fedele L; Strina I; Massobrio M; Ragni N; De Placido G
Reprod Biol Endocrinol; 2007 Dec; 5():45. PubMed ID: 18053198
[TBL] [Abstract][Full Text] [Related]
2. A prospective, randomised, investigator-blind, controlled, clinical study on the clinical efficacy and tolerability of two highly purified hMG preparations administered subcutaneously in women undergoing IVF.
Alviggi C; Cognigni GE; Morgante G; Cometti B; Ranieri A; Strina I; Filicori M; De Leo V; De Placido G
Gynecol Endocrinol; 2013 Jul; 29(7):695-9. PubMed ID: 23638621
[TBL] [Abstract][Full Text] [Related]
3. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
[TBL] [Abstract][Full Text] [Related]
4. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
[TBL] [Abstract][Full Text] [Related]
5. Randomised controlled trial on the effect of clomiphene citrate and gonadotropin dose on ovarian response markers and IVF outcomes in poor responders.
Moffat R; Hansali C; Schoetzau A; Ahler A; Gobrecht U; Beutler S; Raggi A; Sartorius G; De Geyter C
Hum Reprod; 2021 Mar; 36(4):987-997. PubMed ID: 33367742
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
Hompes PG; Broekmans FJ; Hoozemans DA; Schats R;
Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized study to assess the clinical efficacy of gonadotrophins administered subcutaneously and intramuscularly.
Engmann L; Shaker A; White E; Bekir JS; Jacobs HS; Tan SL
Hum Reprod; 1998 Apr; 13(4):836-40. PubMed ID: 9619533
[TBL] [Abstract][Full Text] [Related]
8. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
[TBL] [Abstract][Full Text] [Related]
9. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
Zhu X; Ye H; Fu Y
Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
[TBL] [Abstract][Full Text] [Related]
10. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial.
Wang Y; Chen Q; Wang N; Chen H; Lyu Q; Kuang Y
Medicine (Baltimore); 2016 Mar; 95(9):e2939. PubMed ID: 26945402
[TBL] [Abstract][Full Text] [Related]
11. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization.
Avrech OM; Orvieto R; Pinkas H; Sapir-Rufas O; Feldberg D; Fisch B
Gynecol Endocrinol; 2004 Nov; 19(5):247-52. PubMed ID: 15726912
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI.
Bjercke S; Tanbo T; Abyholm T; Omland A; Opøien HK; Fedorcsak P
Acta Obstet Gynecol Scand; 2010 Aug; 89(8):1053-60. PubMed ID: 20602599
[TBL] [Abstract][Full Text] [Related]
13. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study.
Westergaard LG; Erb K; Laursen SB; Rex S; Rasmussen PE
Fertil Steril; 2001 Sep; 76(3):543-9. PubMed ID: 11532479
[TBL] [Abstract][Full Text] [Related]
14. A prospective comparative study on IVF outcomes with either purified FSH or human menopausal gonadotrophin in downregulated normogonadotrophic women.
Ismail AF; Hesham AI; Salah Z; Khaled M; Fouad N; Ashraf N; Hatem S; Hamdi B
Gynecol Obstet Invest; 2002; 53(4):220-3. PubMed ID: 12186987
[TBL] [Abstract][Full Text] [Related]
15. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial.
Youssef MA; van Wely M; Al-Inany H; Madani T; Jahangiri N; Khodabakhshi S; Alhalabi M; Akhondi M; Ansaripour S; Tokhmechy R; Zarandi L; Rizk A; El-Mohamedy M; Shaeer E; Khattab M; Mochtar MH; van der Veen F
Hum Reprod; 2017 Jan; 32(1):112-118. PubMed ID: 27836979
[TBL] [Abstract][Full Text] [Related]
16. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
[TBL] [Abstract][Full Text] [Related]
17. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.
Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA
Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119
[TBL] [Abstract][Full Text] [Related]
18. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation.
Zhu X; Ye H; Fu Y
Fertil Steril; 2017 Sep; 108(3):505-512.e2. PubMed ID: 28697910
[TBL] [Abstract][Full Text] [Related]
19. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
[TBL] [Abstract][Full Text] [Related]
20. Clinical comparison of ovarian stimulation and luteal support agents in patients undergoing GnRH antagonist IVF cycles.
Miller CE; Zbella E; Webster BW; Doody KJ; Bush MR; Collins MG
J Reprod Med; 2013; 58(3-4):153-60. PubMed ID: 23539885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
